Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: Results of a prospective 5-year study

Cutis

Volumn 85, Issue 6, 2010, Pages 318-324

  Quirk, Christopher ^a   Gebauer, Kurt ^b   De'Ambrosis, Brian ^c   Slade, Herbert B ^d   Meng, Tze Chiang ^e  

^a Dermatology Specialist Group   (Australia)

^b Fremantle Dermatology   (Australia)

^c Southeast Dermatology Centre   (Australia)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^e Graceway Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIQUIMOD;

ARTICLE; BASAL CELL CARCINOMA; CLINICAL TRIAL; FOLLOW UP; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; SKIN TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADMINISTRATION, CUTANEOUS; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FOLLOW-UP STUDIES; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77955778580     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med. 1992;327:1649-1662.
2. Roewert-Huber J, Lange-Asschenfeldt B, Stockfleth E, et al. Epidemiology and aetiology of basal cell carcinoma. Br J Dermatol. 2007;157:47-51.
3. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol. 2002;146(suppl 61):1-6.
4. Tilli CM, Van Steensel MA, Krekels GA, et al. Molecular aetiology and pathogenesis of basal cell carcinoma. Br J Dermatol. 2005;152:1108-1124.
5. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis. 2005;26:1657-1667.
6. Schwarz A, Schwarz T. Molecular determinants of UV-induced immunosuppression. Exp Dermatol. 2002;11(suppl 1):9-12.
7. Bowers B, Sasset-Seguin N, Colver G, et al; on behalf of the European Dermatology Forum. Guidelines for the management of basal cell carcinoma. 2004/2008. http://www.euroderm.org/. Accessed May 17, 2010.
8. Telfer NR, Colver GB, Morton CA; British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 2008;159:35-48.
9. Cancer Council Australia and Australian Cancer Network, Sydney. Basal cell carcinoma, squamous cell carcinoma (and related lesions): a guide to clinical management in Australia. November 2008. http://www.cancer.org.au/File/BasalcellcarcinomaSquamouscellcarcinomaGuideNov2008Final.pdf. Accessed May 17, 2010.
10. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Microbes Infect. 2004;6:1382-1387.
11. Gaspari AA, Sauder DN. Immunotherapy of basal cell carcinoma: evolving approaches. Dermatol Surg. 2003;29:1027-1034.
12. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-733.
13. Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939-947.
14. Quirk C, Gebauer K, Owens M, et al. Two-year interim results from a 5-year study evaluating clinical recurrence of superficial basal cell carcinoma after treatment with imiquimod 5% cream daily for 6 weeks. Australas J Dermatol. 2006;47:258-265.
15. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe. Eur J Dermatol. 2005;15:374-381.
16. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18:677-682.
17. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15:315-328.
18. Su SY, Giorlando F, Ek EW, et al. Incomplete excision of basal cell carcinoma: a prospective trial. Plast Reconstr Surg. 2007;120:1240-1248.
19. Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol. 1991;17:574-578.
20. Silverman MK, Kopf AW, Bart RS, et al. Recurrence rates of treated basal cell carcinomas. part 3: surgical excision. J Dermatol Surg Oncol. 1992;18:471-476.
21. Werlinger KD, Upton G, Moore AY. Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation-curettage in a private dermatological practice. Dermatol Surg. 2002;28:1138-1142.
22. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18:547-553.
23. Topical imiquimod compared with surgery in treating patients with basal cell skin cancer. NCT00066872. http://www.clinicaltrials.gov/. Accessed May 17, 2010.